Skip to main content
TGTX
NASDAQ Life Sciences

Shareholders Reject Executive Compensation, Show High Dissent for Board Members at Annual Meeting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$49.4
Mkt Cap
$7.581B
52W Low
$25.28
52W High
$50.41
52W Position info
95% above low
Off High info
2.0% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

TGTX sits 95% above its 52-week low of $25.28.

Summary

TG Therapeutics shareholders rejected the advisory vote on executive compensation and showed significant dissent for certain board members at the 2026 Annual Meeting, highlighting a governance challenge despite recent positive operational news.


Key Events · Corporate Governance and Compliance · TGTX

  • Executive Compensation Rejected

    Shareholders voted against the advisory proposal to approve the compensation of named executive officers, with 48,858,169 votes against compared to 31,905,837 for. This follows a previous proxy statement indicating low approval for 2025 executive compensation.

  • Significant Dissent for Board Members

    While all six directors were re-elected, two board members, Kenneth Hoberman and Sagar Lonial, MD, received high 'withheld' votes of 34.48% and 45.15% respectively, indicating notable shareholder dissatisfaction with their positions.

  • Auditor Ratification Approved

    KPMG LLP was ratified as the independent registered public accounting firm for 2026 with overwhelming support, receiving 112,329,330 votes for.


Analysis · TGTX · Life Sciences

Shareholders rejected the advisory vote on executive compensation, indicating significant dissatisfaction with the company's pay practices. This outcome, coupled with substantial 'withheld' votes for two directors, signals a notable governance challenge for the board and management. This is particularly striking given the company's recent strong operational performance and positive clinical trial results, suggesting a disconnect between shareholder sentiment on governance and the company's business momentum. The board will likely face pressure to address these concerns.

At the time of this filing, TGTX was trading at $49.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $25.28 to $50.41. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Jun 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $42.00
Real-time Price: $55.75 info
Change: +$13.75 (+33%) info
Market Cap: $8.534B info
TGTX
Jun 03, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.65
Real-time Price: $55.75 info
Change: +$19.10 (+52%) info
Market Cap: $8.534B info
TGTX
Jun 03, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $36.95
Real-time Price: $55.75 info
Change: +$18.80 (+51%) info
Market Cap: $8.534B info
TGTX
May 27, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.20
Real-time Price: $55.75 info
Change: +$16.55 (+42%) info
Market Cap: $8.534B info
TGTX
May 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $41.08
Real-time Price: $55.75 info
Change: +$14.67 (+36%) info
Market Cap: $8.534B info